Leflunomide-mediated suppression of antiviral antibody and T cell responses: Differential restoration by uridine

Transplantation

Volumn 72, Issue 4, 2001, Pages 712-719

  Pinschewer, Daniel D ^a,b   Ochsenbein, Adrian F ^a   Fehr, Thomas ^a,c   Zinkernagel, Rolf M ^a  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; LEFLUNOMIDE; PYRIMIDINE; URIDINE; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG MECHANISM; HELPER CELL; HUMORAL IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; VESICULAR STOMATITIS VIRUS; VIRUS MENINGITIS;

EID: 0035959338     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200108270-00026     Document Type: Article

References (52)

1. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment
2. Induction of species-specific host accommodation in the hamster- to-rat xenotransplantation model
3. Leflunomide controls rejection in hamster to rat cardiac xenografts
4. In vivo activity of leflunomide: Pharmacokinetic analyses and mechanism of immunosuppression
5. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat
6. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice
7. Leflunomide prevents the development of experimentally induced myasthenia gravis
8. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
9. Clinical improvement as refected in measures of function and health related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial
10. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide
11. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine
12. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy- crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide
13. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production
14. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms
15. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano- beta-hydroxy-beta- methyl-N-(2, 5-Dibromophenyl)Propenamide]
16. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
17. Regulation of B cell function by the immunosuppressive agent leflunomide
18. Role of Btk in B cell development and signaling
19. Protective effect of leflunomide on the natural course of Leishmania major-induced disease in genetically susceptible BALB/c mice
20. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice
21. Neutralizing antiviral B cell responses
22. MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness
23. The virology and immunobiology of lymphocytic choriomeningitis virus infection
24. Lymphocytic choriomeningitis virus
25. The biology of lymphocytic choriomeningitis infection: Virus induced immune disease
26. Virus-triggered acquired immunodeficiency by cytotoxic T-cell- dependent destruction of antigen-presenting cells and lymph follicle structure
27. Baculovirus expression vectors: The requirements for high level expression of proteins, including glycoproteins
28. Glycosylation is not required for the fusion activity of the G protein of vesicular stomatitis virus in insect cells
29. Quantification of lymphocytic choriomeningitis Virus with an immunological focus assay in 24- or 96-well plates
30. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D
31. Induction of long-lived germinal centers associated with persisting antigen after viral infection
32. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells
33. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
34. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts
35. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction?
36. Antiviral protection and germinal center formation, but impaired B cell memory in the absence of CD19
37. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide
38. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity
39. Quantitation of the changes in splenic architecture during the rejection of cardiac allografts or xenografts
40. Immunosuppression by lymphocytic choriomeningitis virus infection: Competent effector T and B cells but impaired antigen presentation
41. Immune responses in interleukin-2-deficient mice
42. Analysis of the kinetics of antiviral memory T help in vivo: Characterization of short-lived cross-reactive T help
43. Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes
44. T-cell populations specifically depleted of allo-reactive potential cannot be induced to lyse H-2-different virus-infected target cells
45. Functional analysis of T lymphocyte subsets in antiviral host defense
46. Enzymes of nucleotide biosynthesis: Differences between intact and lysed cells as well as between species and tissues can be important
47. Importance of ribonucleotide availability to proliferating T- lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
48. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells
49. Uridine transport in concanavalin A- and lipopolysaccharide-activated mouse lymphocytes
50. Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-alpha
51. Opportunistic fungal and bacterial infection in the renal transplant recipient
52. Cytomegalovirus epididymitis following renal transplantation